AstraZeneca Pharma India Ceases Manufacturing Operations in Strategic Pivot to Office-Based Model
Key Insights
AstraZeneca Pharma India reported a turnover of ₹2,275.58 crore for FY 2025-26, with export sales contributing ₹117.56 crore (5.2% of total turnover).
The company has ceased all manufacturing operations, marking a fundamental strategic shift to an office-based business model serving Pan-India and international markets including Nepal.
The company's net worth stood at ₹872.79 crore, with board diversity reaching 83.33% women directors (5 out of 6 board members).
AstraZeneca Pharma India Limited has released its Business Responsibility and Sustainability Report (BRSR) for the financial year ended 31 March 2026, disclosing a significant operational transformation: the company has ceased all manufacturing activities and pivoted to an office-based operational model. The filing, submitted in accordance with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, reveals a turnover of ₹2,275.58 crore and a net worth of ₹872.79 crore for the fiscal year.
The cessation of manufacturing represents a fundamental restructuring of the company's asset base and operational framework. According to the regulatory filing, the company's reporting boundary has been adjusted to include shared office spaces following the manufacturing shutdown, and its business model is now centered on office-based operations with continued focus on its science-led pharmaceutical business.
Financial Performance and Market Reach
For FY 2025-26, AstraZeneca Pharma India recorded a turnover of ₹2,275.58 crore (INR 22,755.8 million), with export sales contributing ₹117.56 crore (INR 1,175.6 million), representing 5.2% of total turnover. The company operates primarily in the domestic pharmaceutical market, serving a diverse customer base that includes distributors, hospitals, and government institutions across India, with international operations extending to Nepal.
The company currently employs 760 people, with women accounting for 22% of its workforce. Notably, board diversity stands at 83.33%, with five out of six directors being women.
Sustainability Commitments and Environmental Metrics
Aligned with AstraZeneca Group's global strategy, the company continues to advance its sustainability agenda under the Ambition Zero Carbon programme, which aims to reduce greenhouse gas emissions while enabling business growth. For FY 2025-26, the company reported energy consumption of 10,477.20 GJ and water withdrawal of 8,203.32 kiloliters. These metrics have been restated to ensure year-on-year comparability.
The Director's message within the report underscores AstraZeneca's commitment to creating a responsible, resilient, and sustainable business model, with a focus on addressing major health challenges by enhancing health equity and health systems resilience through innovation and collaboration with governments, health systems, patient groups, academia, and NGOs.
Assurance and Transparency
KPMG Assurance and Consulting Services LLP has provided a Limited Assurance report on the BRSR Core Indicators, enhancing the credibility and transparency of the company's disclosures. The BRSR report identifies material issues crucial to the company's operations, spanning from climate action to sustainable patient care.
Strategic Outlook
The manufacturing cessation signals a strategic pivot that investors will need to monitor closely. The company's ability to maintain its market presence and financial health under the new office-based operational model, while progressing toward its decarbonisation goals under Ambition Zero Carbon, will be key indicators of the strategy's success. AstraZeneca Pharma India, established in 1979 and headquartered in Bangalore, Karnataka, remains a globally recognised pharmaceutical entity focused on the development and commercialisation of prescription medicines.